We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
- Authors
Dekker, Adriaan W.; NieuwenhuisKarel, H. Karel; Verdonck, Leo F.; Dekker, A W; Nieuwenhuis, H K; Verdonck, L F
- Abstract
Results of remission induction therapy in refractory acute nonlymphocytic leukemia (ANLL) has been improved since the introduction of high-dose cytosine arabinoside. However, the toxicity of these regimens attributes to an early death rate of about 20% to 30%. The authors treated 37 poor-risk patients with ANLL with intermediate-dose cytosine arabinoside and amsacrine for remission induction. One consolidation course and no maintenance therapy was given. Eleven of 19 patients with a first relapse entered complete remission (58%); ten of 15 patients in this group older than 50 years were complete responders (67%). Median duration of second remission was 8.2 months (range, 2-14). Three of 13 patients with primarily resistant disease had a complete remission (23%), but there was no response in five patients with a myeloid blastic phase of chronic myelogenous leukemia. Side effects of this remission induction regimen were mild; no cardiac, pulmonary, or central nervous system toxicity was observed. Five patients (14%) died during the remission induction phase, three from complications during aplasia and two from refractory leukemia.
- Publication
Cancer (0008543X), 1990, Vol 65, Issue 9, p1891
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19900501)65:9<1891::AID-CNCR2820650903>3.0.CO;2-5